Repligen | RGEN - Ebitda


Repligen reported $40.01M in EBITDA for its fiscal quarter ending in March of 2026.





Ebitda Change Date
Agilent USD 456M 84M Dec/2025
Align Technology USD 260.87M 77.03M Dec/2025
Bio Techne USD 116.71M 13.29M Mar/2026
BioMarin Pharmaceutical USD 146.05M 170.22M Mar/2026
Bristol-Myers Squibb USD 2.88B 1.36B Dec/2025
Bruker USD 110M 101.6M Mar/2026
Charles River Laboratories USD 229.8M 28.26M Mar/2026
Danaher USD 1.92B 204M Mar/2026
Dentsply International USD 129M 6M Mar/2026
General Electric Aerospace USD 2.84B 568M Mar/2026
Henry Schein USD 289M 2M Mar/2026
Illumina USD 469M 137M Dec/2025
IQVIA Holdings USD 932M 114M Mar/2026
Mettler Toledo International USD 278.99M 100.24M Mar/2026
Myriad Genetics USD 14.3M 4M Dec/2025
OraSure Technologies USD -17.7M 4.06M Dec/2025
Pacific Biosciences Of California USD -35.4M 5.78M Sep/2025
Pfizer USD 5.99B 5.23B Mar/2026
Repligen USD 40.01M 469K Mar/2026
Revvity USD 272.91M 24M Mar/2026
Standard Biotools USD -15.81M 734K Dec/2025
Thermo Fisher Scientific USD 2.7B 464M Mar/2026
Waters USD 380.97M 85.83M Dec/2025
West Pharmaceutical Services USD 226.2M 7.7M Mar/2026